Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.45 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.38 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.36 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5664177 | 0.84 | GABRA1 (0.50) | CYP1A2HSD17B10KDM4EMEN1KMT2A | |
| SCHEMBL3836798 | 0.81 | SMN1; SMN2 (0.35) | CYP1A2HSD17B10KDM4ERAB9ANPC1 | |
| SCHEMBL3839419 | 0.76 | MEN1 (0.37) | HSD17B10KDM4ERAB9ANPC1HTT | |
| SCHEMBL3839941 | 0.72 | KDM4E (0.38) | CYP1A2KDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3840520 | 0.70 | CYP1A2 (0.57) | CYP1A2HSD17B10CSNK2A1PIM3CLK4 | |
| SCHEMBL13255383 | 0.70 | RAB9A (0.45) | HSD17B10KDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2309708 | 0.69 | HSD17B10 (0.55) | CYP1A2HSD17B10CSNK2A1PIM3CLK4 | |
| SCHEMBL27773981 | 0.68 | RAB9A (0.46) | HSD17B10KDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3840990 | 0.68 | CYP1A2 (0.54) | CYP1A2HSD17B10CSNK2A1PIM3CLK4 | |
| SCHEMBL22050698 | 0.65 | F7 (0.44) | CYP1A2HSD17B10KDM4ERAB9ATET2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1833830-B1 | QUINOLINE DERIVATIVE, USE AND PRODUCTION THEREOF, AND DRUG CONTAINING THE SAME | BAYER SCHERING PHARMA AG (DE) | 2009-10-14 | — | — | EP | disclosed |
| EP-1833830-A1 | QUINOLINE DERIVATIVE, USE AND PRODUCTION THEREOF, AND DRUG CONTAINING THE SAME | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-09-19 | — | — | EP | disclosed |
| US-20060167035-A1 | Quinoline derivative, its use, production and pharmaceutical agents containing the latter | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-07-27 | — | — | US | disclosed |
| WO-2006066955-A1 | QUINOLINE DERIVATIVE, USE AND PRODUCTION THEREOF, AND DRUG CONTAINING THE SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167035-A1 | Quinoline derivative, its use, production and pharmaceutical agents containing the latter | NQO2, RECQL, XDH | CYP1A2 8/4885HSD17B10 2404/4885CSNK2A1 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.